Bivacor Inc.
Huntington Beach, CA
- UEI
- Y7M1C8XFTFA5
- CAGE
- 72EC1
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5432 Bolsa Ave Suite A, Huntington Beach, CA 92649, USA
- Website
- bivacor.com
- Founded
- 2008
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Geisinger Clinic | R01HL172022 | $107,584 |
Similar vendors
About the company
Bivacor Inc., a for-profit biomedical device developer based in Huntington Beach, California, is a federal grant recipient developing rotary total artificial heart (TAH) systems for adult and pediatric end-stage heart failure under National Institutes of Health funding. The company operates exclusively as a prime grant recipient and as a sub-recipient on NIH-funded research collaborations, with no federal contract prime awards in the source record.
Bivacor's federal footprint concentrates entirely within the Department of Health and Human Services' National Institutes of Health, National Heart Lung and Blood Institute (NHLBI), which accounts for all four awards in the source record totaling $17.3 million obligated. The vendor's capability work centers on design, development, and clinical validation of a small, durable rotary blood pump intended to replace complete heart function in patients with biventricular failure — a population for which transplantation remains the only alternative and donor availability is severely constrained. Recent prime grant work includes a project grant awarded August 1, 2023 (completion July 31, 2026) to conduct the first clinical use of the Bivacor TAH via an FDA-approved early feasibility study, advancing the device from benchtop and in-vivo validation toward human trials. A second prime project grant awarded August 5, 2021 (completion July 31, 2025) targeted pediatric adaptations of the TAH system, addressing the urgent unmet need for long-term mechanical circulatory support in children with end-stage heart failure.
In its sub-recipient role, Bivacor provided technical and manufacturing expertise under a sub-award from Geisinger Clinic (prime recipient on an NIH R01 application) dated April 1, 2026, supplying eight TAH systems, controllers, and consoles, plus surgical implantation expertise and engineering support for bovine animal studies investigating pulsatile versus continuous artificial circulation. Activity is sparse but sustained over nine years — one award per award year in 2017, 2021, 2023, and 2026 — with one award (the pediatric TAH project) reaching ultimate completion within the next twenty-four months.
Quick answers
Is Bivacor Inc. registered in SAM.gov?
Yes. Bivacor Inc.'s SAM.gov registration is active through December 19, 2026.
What is Bivacor Inc.'s most recent federal award?
Bivacor Inc.'s most recent federal grant award is The first clinical use of the bivacor total artificial heart (R44HL167582), from National Heart Lung and Blood Institute (NIH), on August 1, 2023.
On GovTribe
See Bivacor Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors